IMpower010: biomarkers of disease-free survival (DFS) in a Phase 3 study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC
This presentation reports biomarker analyses from IMpower010, a randomized, open-label, phase III study of adjuvant atezolizumab compared with best supportive care in patients with completely resected stage IB-IIIA NSCLC who received adjuvant cisplatin-based chemotherapy. Exploratory disease-free survival results by PD-L1 subgroups and EGFR/ALK status are reported, as well as an assessment of post-resection ctDNA as a potential prognostic or predictive biomarker in patients with stage II-IIIA NSCLC.